title: Clinical features and prognostic factors in solitary plasmacytoma.
abstract: This study aimed to review the clinical features and outcome of 53 patients with solitary plasmacytoma managed at our Institution between 1976 and 2012. Thirty-five patients had bone solitary plasmacytoma and 18 extramedullary solitary plasmacytoma. Tumour sizes were larger in patients with bone involvement (P = 0·003). Treatment consisted of local radiotherapy (n = 26), radiotherapy + chemotherapy (n = 15), surgery (n = 4) and chemotherapy (n = 8); the local control rate was 94·3%. Progression to multiple myeloma was recorded in 20/35 (57·1%) patients with bone involvement and in 1/18 (5·5%) patients with extramedullary disease (P = 0·0003). The 5-year overall survival (OS) rate was 78·4%; bone solitary plasmacytoma patients had a significantly worse OS (71·9% vs. 88·2%, respectively; P = 0·029) and 5-year progression-free survival (PFS; 53·0% vs. 88·5%; P = 0·0003) compared to extramedullary solitary plasmacytoma patients. On univariate analysis, bone disease and size (≥5 cm) impacted negatively on PFS (P = 0·0027 and P = 0·04, respectively). Bone disease also affected OS (P = 0·04). In multivariate analysis bone location was the only independent prognostic factor for PFS (P = 0·0041) and OS (P = 0·021). Patients with bone solitary plasmacytoma have a significantly worse prognosis than extramedullary solitary plasmacytoma cases.
authors.affiliation: Haematology Division, Department of Cellular Biotechnologies and Haematology, 'Sapienza' University, Rome, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Finsinger
authors.affiliation: Haematology Division, Department of Cellular Biotechnologies and Haematology, 'Sapienza' University, Rome, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Grammatico
authors.affiliation: Haematology Division, Department of Cellular Biotechnologies and Haematology, 'Sapienza' University, Rome, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Chisini
authors.affiliation: GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Piciocchi
authors.affiliation: Haematology Division, Department of Cellular Biotechnologies and Haematology, 'Sapienza' University, Rome, Italy.
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
authors.affiliation: Haematology Division, Department of Cellular Biotechnologies and Haematology, 'Sapienza' University, Rome, Italy.
authors.forename: Maria T
authors.initials: MT
authors.lastname: Petrucci
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000209:etiology / Q000401:mortality / Q000473:pathology; D010954:Plasmacytoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents
keywords: bone plasmacytoma; extramedullary plasmacytoma; multiple myeloma progression; plasmacytoma; prognostic factors